Medicine

Successful eradication of molecular measurable residual disease with pegylated interferon alfa-2b in two pediatric cases of RUNX1::RUNX1T1 AML: a report of two cases and literature review.

Juanjuan Li, W. Fan, Zhaoxia Zhang, Ze-liang Song, Binghang Zou, D. Zhong, R. Tang, M. Yue, M. Hu, L. Xuan, Honghong Qin, Xiaona Chen, Rong Liu

2026.6.14LEUKEMIA & LYMPHOMA

DOI: 10.1080/10428194.2026.2679591

Abstract

To the EditorRUNX1::RUNX1T1 AML is classified as favorable-risk by ELN criteria, with 5-year EFS of 70–80% in children [1,2]. However, 25–40% of patients have persistent MRD after consolidation, st...

Citation format

LI, Juanjuan, et al. Successful eradication of molecular measurable residual disease with pegylated interferon alfa-2b in two pediatric cases of RUNX1::RUNX1T1 AML: A report of two cases and literature review. LEUKEMIA & LYMPHOMA, 2026: 1–4.